Cardiff Oncology shares plunge after Q2 earnings miss
Boston Scientific Corp (NYSE:BSX) Senior Vice President, General Counsel, and Corporate Secretary, Vance R. Brown, executed a sale of company shares totaling $486,702. The transaction, which took place on March 21, 2025, involved the sale of 4,826 shares at a price of $100.85 each. The healthcare equipment giant, with a market capitalization of $152 billion, has seen its stock surge nearly 49% over the past year, trading near its 52-week high. According to InvestingPro analysis, the stock is currently trading above its Fair Value.
Following this sale, Brown holds 41,019 shares of Boston Scientific. The transaction was conducted under a pre-established Rule 10b5-1 trading plan adopted on November 21, 2024. Analysts maintain a strong bullish outlook on BSX, with price targets ranging from $84 to $135 per share. For deeper insights into Boston Scientific’s valuation and growth prospects, including 16 additional exclusive ProTips, check out the comprehensive research report available on InvestingPro.
In other recent news, Boston Scientific Corporation has announced a series of significant developments. The company reported a robust performance, with S&P Global upgrading its credit rating to ’A-’ from ’BBB+’ due to strong organic growth and free cash flow. Fitch Ratings also upgraded Boston Scientific’s Long-Term Issuer Default Rating to ’A-’, highlighting the company’s operational success and innovative product launches. The firm’s revenue for 2024 reached $16.7 billion, marking a 17.6% increase from the previous year, driven by successful product commercialization and strategic acquisitions.
RBC Capital Markets reiterated its Outperform rating for Boston Scientific, citing the company’s resilience to economic disruptions and strong uptake of its technologies. Analysts from RBC anticipate revenue growth and operating margin expansion, with a positive outlook on the company’s future prospects. Meanwhile, Jefferies analyst Matthew Taylor issued a Buy rating for Boston Scientific, contrasting with his Hold ratings for other companies in the sector.
In governance news, Boston Scientific announced that board member Charles J. Dockendorff will not seek re-election at the 2025 Annual Meeting of Stockholders. The company is currently evaluating whether to add new directors following his departure. These recent developments reflect Boston Scientific’s strategic focus on growth and innovation in the medical device industry.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.